◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › O › OPK

Opko Health Inc (OPK) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-09-16

Opko Health Inc (OPK) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Miami, United States with about 2,275 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, OPK reported $607M in revenue and ($226M) in net income.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.

Interactive charts & full statements → Open the OPK valuation workbench →

OPK Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$588M	$607M	$713M	$863M	$1.0B	$1.8B	$1.4B	$902M	$990M	$966M	$1.2B	$492M	$91M	$97M	$47M	$28M	$28M	$13M	$9M	$1M	—
Gross Profit	$182M	$128M	$311M	$318M	$288M	$582M	$541M	$329M	$386M	$346M	$610M	($98M)	($146M)	$48M	$19M	$11M	$15M	$4M	$1M	$0M	—
Gross Margin %	30.9%	21.1%	43.6%	36.8%	28.7%	32.8%	37.7%	36.5%	39.0%	35.8%	50.0%	-20.0%	-160.0%	49.4%	40.7%	38.4%	52.6%	27.2%	9.3%	4.6%	—
Operating Income (EBIT)	($150M)	($219M)	($152M)	($157M)	($226M)	$19M	$58M	($274M)	($171M)	($276M)	($73M)	($98M)	($146M)	($80M)	($37M)	($23M)	($11M)	($23M)	($37M)	($268M)	($1M)
Operating Margin %	-25.5%	-36.1%	-21.3%	-18.2%	-22.5%	1.1%	4.0%	-30.4%	-17.3%	-28.6%	-6.0%	-20.0%	-160.0%	-82.5%	-79.2%	-82.9%	-39.1%	-173.6%	-393.7%	-31624.4%	—
Net Income	($72M)	($226M)	($53M)	($189M)	($328M)	($30M)	$31M	($315M)	($153M)	($305M)	($48M)	($30M)	($172M)	($114M)	($29M)	($1M)	($19M)	($30M)	($40M)	($268M)	($1M)
Net Margin %	-12.2%	-37.2%	-7.5%	-21.9%	-32.7%	-1.7%	2.1%	-34.9%	-15.4%	-31.6%	-4.0%	-6.1%	-188.5%	-118.5%	-61.8%	-4.6%	-66.4%	-229.1%	-422.0%	-31688.9%	—
EBITDA	$47M	($41M)	$135M	($66M)	($271M)	$84M	$156M	($190M)	($68M)	($163M)	$7M	($56M)	($131M)	($75M)	($26M)	($19M)	($9M)	($23M)	($35M)	($24M)	($1M)
Earnings Per Share (EPS)	$-0.09	$-0.30	$-0.08	$-0.25	$-0.46	$-0.05	$0.05	$-0.53	$-0.27	$-0.55	$-0.10	$-0.06	$-0.41	$-0.32	$-0.10	$-0.00	$-0.07	$-0.13	$-0.21	$-2.08	$-0.04
Shares Outstanding (M)	755M	751M	694M	752M	719M	648M	641M	595M	567M	559M	502M	500M	419M	355M	296M	281M	255M	233M	188M	—	16M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OPK Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$164M	$124M	$148M	$152M	$157M	$150M	$184M	$174M
Gross Profit	$80M	$27M	$45M	$30M	$30M	$23M	$85M	$40M
Gross Margin %	48.9%	21.6%	30.3%	20.0%	19.1%	15.2%	46.1%	23.1%
Operating Income (EBIT)	($7M)	($51M)	($38M)	($54M)	($60M)	($67M)	($33M)	$14M
Operating Margin %	-4.3%	-41.1%	-25.8%	-35.3%	-38.2%	-44.8%	-18.1%	8.2%
Net Income	($8M)	($55M)	($31M)	$22M	($148M)	($68M)	$14M	$25M
Net Margin %	-5.1%	-44.2%	-21.1%	14.3%	-94.7%	-45.1%	7.6%	14.3%
EBITDA	$12M	($28M)	($13M)	$76M	($69M)	($34M)	$73M	$90M
Earnings Per Share (EPS)	$-0.01	$-0.07	$-0.04	$0.03	$-0.19	$-0.10	$0.02	$0.04
Shares Outstanding (M)	755M	759M	766M	780M	788M	672M	694M	696M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OPK Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($124M)	($179M)	($183M)	($28M)	($95M)	$38M	$39M	($173M)	($109M)	($92M)	$32M	$164M	($90M)	($58M)	($25M)	($18M)	($19M)	($23M)	($29M)	($17M)	$0M
Capital Expenditures (CapEx)	$11M	$12M	$25M	$16M	$25M	$32M	$34M	$13M	$28M	$47M	$24M	$16M	$5M	$4M	$1M	$2M	$1M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($135M)	($191M)	($208M)	($44M)	($120M)	$6M	$6M	($185M)	($137M)	($139M)	$8M	$148M	($95M)	($62M)	($27M)	($20M)	($20M)	($24M)	($30M)	($17M)	$0M
FCF Margin %	-23.0%	-31.4%	-29.2%	-5.1%	-11.9%	0.4%	0.4%	-20.5%	-13.8%	-14.3%	0.7%	30.1%	-104.4%	-64.4%	-57.1%	-73.1%	-69.7%	-178.8%	-314.3%	-2058.8%	—
Dividends Paid	—	—	—	—	—	—	—	$0M	—	$0M	$0M	$0M	$0M	$3M	$0M	$5M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OPK Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($44M)	($19M)	($26M)	($35M)	($83M)	($35M)	($44M)	($77M)
Capital Expenditures (CapEx)	$3M	$2M	$3M	$3M	$3M	$3M	$5M	$8M
Free Cash Flow (FCF)	($47M)	($21M)	($29M)	($38M)	($87M)	($38M)	($50M)	($85M)
FCF Margin %	-28.4%	-17.0%	-19.3%	-24.9%	-55.3%	-25.2%	-27.1%	-49.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OPK Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.8B	$1.9B	$2.2B	$2.0B	$2.2B	$2.4B	$2.5B	$2.3B	$2.5B	$2.6B	$2.8B	$2.8B	$1.3B	$1.4B	$290M	$229M	$78M	$87M	$22M	$40M	$9M
Cash & Cash Equivalents	$301M	$369M	$432M	$96M	$153M	$135M	$72M	$85M	$96M	$91M	$169M	$194M	$97M	$186M	$27M	$72M	$18M	$43M	$7M	$23M	$9M
Total Liabilities	$645M	$664M	$835M	$622M	$606M	$715M	$802M	$694M	$660M	$746M	$675M	$820M	$432M	$519M	$87M	$69M	$55M	$30M	$21M	$23M	$1M
Total Debt (Short + Long-Term)	$360M	$357M	$452M	$265M	$270M	$216M	$262M	$284M	$208M	$150M	$98M	$117M	$147M	$228M	$23M	$9M	$15M	$16M	$12M	$14M	$0M
Total Shareholders' Equity	$1.2B	$1.3B	$1.4B	$1.4B	$1.6B	$1.7B	$1.7B	$1.6B	$1.8B	$1.8B	$2.1B	$2.0B	$836M	$876M	$204M	$161M	$23M	$58M	$0M	$17M	$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OPK viewer.

Other Companies in DIAGNOSTICS & RESEARCH

WGS · GeneDx Holdings Corp. — $3 billion
CDNA · CareDx Inc — $3 billion
FRNM · Freenome, Inc. Common stock — $2 billion
PSNL · Personalis Inc — $2 billion
CSTL · Castle Biosciences Inc — $1 billion
NTRA · Natera Inc — $53 billion
ILMN · Illumina Inc — $36 billion
GH · Guardant Health Inc — $24 billion

← OPFI All “O” companies OPLN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.